This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo


Oral formulations of dimethyl fumarate.

Drugs List

  • dimethyl fumarate 120mg gastro-resistant tablets
  • dimethyl fumarate 30mg gastro-resistant tablets
  • SKILARENCE 120mg gastro-resistant tablets
  • SKILARENCE 30mg gastro-resistant tablets
  • Therapeutic Indications


    Moderate to severe plaque psoriasis



    The starting dose is 30mg once a day.

    Dose is increased by 1 tablet weekly until treatment success or increase not tolerated. Following improvement of skin lesions gradual reduction of daily dose should be considered to achieve maintenance.

    Week 1: 30mg once a day (evening).
    Week 2: 30mg twice a day (morning and evening).
    Week 3: 30mg three times a day (morning, noon, and evening).
    Week 4: 120mg once a day (evening).
    Week 5: 120mg twice a day (morning and evening).
    Week 6: 120mg three times a day (morning, noon, and evening).
    Week 7: 120mg twice a day and 240mg once a day (evening).
    Week 8: 120mg once a day and 240mg twice a day (morning and evening).
    Week 9 and beyond: 240mg three times a day (morning, noon, and evening).

    If a dose increase is not tolerated it may be temporarily reduced to the last tolerated dose.


    Children under 18 years
    Leucocytes below 3 x 10 to power of 9/L at baseline
    Lymphocytes below 1 x 10 to power of 9/L at baseline
    Severe infection
    Severe gastrointestinal disorder
    Severe hepatic impairment
    Severe renal impairment

    Precautions and Warnings

    Antibodies to JC virus
    Females of childbearing potential
    Glucose-galactose malabsorption syndrome
    Lactose intolerance

    Administration of live vaccines is not recommended
    Treatment to be initiated and supervised by a specialist
    Contains lactose
    A recent (within 3 months) MRI should be available prior to treatment
    Monitor renal and hepatic function before and during treatment
    Monitor serum transaminases (including ALT) before and during therapy
    Perform full blood count before treatment
    Monitor full blood counts every 3 months
    Monitor monthly if lymphocyte count falls below 1x10 to power 9/L
    Advise patient that flushing reactions may occur
    Advise patient to report headaches, seizures, confusion, visual disturbance
    Advise patient to report symptoms of infection immediately
    Advise patient to seek medical advice if severe flushing occurs
    Discontinue if anaphylactoid reaction occurs
    Discontinue if leucocyte count falls below 3x10 to power of 9/L
    Discontinue if lymphocyte count falls below 0.7x10 to power 9/L
    Discontinue if Progressive multifocal leukoencephalopathy (PML) develops
    Discontinue treatment if patient develops a serious infection
    Advise patient to moderate alcohol intake during treatment
    Female: Ensure adequate contraception during treatment
    Female: Oral contraception may not be adequate during treatment

    Prior to initiating treatment with dimethyl fumarate, a recent complete blood count (within 6 months) should be available. Assessments of complete blood counts are also recommended every 3 months and as clinically indicated.

    Assessments of renal function (e.g. creatinine, blood urea nitrogen and urinalysis) are recommended prior to treatment initiation, after 3 and 6 months and then every 6 to 12 months thereafter as clinically indicated.

    If lymphocyte counts are found to be below the normal range prior to treatment, assessments of the possible causes should be completed prior to the initiation of dimethyl fumarate treatment.

    Progressive multifocal leukoencephalopathy syndrome (PML) has been reported in some patients treated with this agent. If patients present with symptoms indicating PML such as worsening neurological, cognitive or behavioural signs or symptoms, an MRI should be performed. If PML is diagnosed, treatment should be permanently discontinued.

    Consider a short course of acetylsalicylic acid in cases of intolerable flushing.

    Severe flushing as a result of dimethyl fumarate treatment may indicate hypersensitivity.

    Pregnancy and Lactation


    Dimethyl fumarate is contraindicated during pregnancy.

    The manufacturer does not recommend using dimethyl fumarate during pregnancy. Animal studies have shown teratogenic effects. Human data is limited and as such a potential risk cannot be ruled out.


    Dimethyl fumarate is contraindicated during breastfeeding.

    The manufacturer advises that the patient either discontinues dimethyl fumarate or discontinues breastfeeding. The presence of dimethyl fumarate in human breast milk and the effects on exposed infants are unknown.

    Side Effects

    Abdominal discomfort
    Abdominal distension
    Abdominal pain
    Acute leukaemia
    Alanine aminotransferase increased
    Allergic skin reactions
    Aspartate aminotransferase increased
    Burning sensation
    Decreased appetite
    Fanconi syndrome
    Feeling hot
    Gastrointestinal disorder
    Hot flushes
    Hypersensitivity reactions
    Increases in hepatic enzymes
    Progressive multifocal leukoencephalopathy (PML)
    Renal failure
    Serum creatinine increased
    Upper abdominal pain
    White blood cell count decreased


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: November 2019

    Reference Sources

    Summary of Product Characteristics: Skilarence 30mg and 120mg gastro-resistant tablets. Almirall Ltd. Revised February 2022.

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.